Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) EBT Margin (2016 - 2025)

Iradimed (IRMD) has disclosed EBT Margin for 13 consecutive years, with 34.42% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 60.0% to 34.42% in Q3 2025 year-over-year; TTM through Sep 2025 was 33.43%, a 31.0% increase, with the full-year FY2024 number at 33.14%, down 1.0% from a year prior.
  • EBT Margin was 34.42% for Q3 2025 at Iradimed, down from 35.9% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 38.83% in Q3 2023 to a low of 18.93% in Q2 2021.
  • A 5-year average of 30.49% and a median of 31.64% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 6178bps in 2021, then tumbled -381bps in 2024.
  • Iradimed's EBT Margin stood at 26.22% in 2021, then grew by 21bps to 31.64% in 2022, then grew by 3bps to 32.56% in 2023, then rose by 1bps to 32.72% in 2024, then increased by 5bps to 34.42% in 2025.
  • Per Business Quant, the three most recent readings for IRMD's EBT Margin are 34.42% (Q3 2025), 35.9% (Q2 2025), and 30.47% (Q1 2025).